Through the expanded relationship CHU de
Nîmes will advance its research of rare and inherited
diseases through pharmacogenomics
BOSTON and ROLLE, Switzerland, Nov. 30,
2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native software company and a leader in data-driven
medicine, today announced that it has expanded its work with
CHU de Nîmes, a regional and university hospital located in the
South of France. The hospital
system will use the SOPHiA DDM™ Platform to progress its
pharmacogenomics research.
Pharmacogenomics research is a field of research that looks at
how an individual's unique genetic profile can affect response to
medications, with the long-term goal to support clinicians in their
choice of drugs and doses to best treat their patients.
"As precision medicine continues to become the gold standard of
care, it's essential that hospitals and organizations like CHU de
Nîmes have access to technologies to help streamline research
and treatment planning, starting with identifying how an
individual's genetic profile influences response to a certain
medication" said Kevin Puylaert, Managing Director, EMEA, SOPHiA
GENETICS. "With the SOPHiA DDM™ Platform, CHU de Nîmes will be
able to advance its pharmacogenomics work, with the aim to
bring about a broader use of personalized treatment plans for the
French patient population."
CHU de Nîmes is a member of the French-speaking group RNPGx, an
international organization of some of the top researchers in the
field of pharmacogenomics. RNPGx aims to further the adoption and
implementation of pharmacogenetics testing.
Top researchers from RNPGx member institutions collaborated with
SOPHiA GENETICS to develop a pharmacogenomics panel. The panel is a
targeted, capture-based NGS panel that will expedite the process of
testing and accelerate pharmacogenomics research.
Additionally, the analytical capabilities of the SOPHiA DDM ™
Platform provide CHU de Nîmes with streamlined insights to
facilitate fast and accurate variant discovery and reporting.
CHU de Nîmes also uses SOPHiA GENETICS' technology for its
research and treatment planning for autism and research of blood
cancers. With the expanded relationship, CHU de Nîmes will
continue to retain ownership of its research database, building
upon the work already done through its use of SOPHiA GENETICS and
helping increase the team's expertise in a variety of research
areas.
For more information, visit SOPHiAGENETICS.COM, or connect
on X, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on X, LinkedIn, Facebook, and Instagram. Where others
see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products, and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-expansion-of-work-with-chu-de-nimes-302000261.html
SOURCE SOPHiA GENETICS